Pulmonary rehabilitation for people with COPD who also have heart or stroke-related vascular disease
Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases
We will test if adding a three-month pulmonary rehabilitation program to usual care helps adults with COPD who also have cardiovascular or cerebrovascular disease reduce flare-ups and improve breathing and quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT07090200 on ClinicalTrials.gov |
What this trial studies
Adults with COPD and coexisting cardiovascular or cerebrovascular disease will be screened, diagnosed, and randomized 1:1 to either routine care or pulmonary rehabilitation plus usual care. The pulmonary rehabilitation group will receive a structured exercise program alongside guideline-directed medications, while the routine group will receive standard pharmacological and non-pharmacological treatments per GOLD recommendations. Key outcomes—annual exacerbation frequency, COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), and lung ventilation and diffusion measures—will be collected and compared one year after the three-month intervention. The project also aims to develop and promote a 'trinity' rehabilitation management model for COPD patients with cardiovascular and cerebrovascular comorbidities.
Who should consider this trial
Good fit: Adults aged 18 or older with diagnosed COPD and coexisting cardiovascular or cerebrovascular disease who can consent and commit to the three-month program and follow-up.
Not a fit: Patients with severe unstable or life-threatening conditions, severe mental illness, pregnant or breastfeeding women, or those unable or unwilling to comply with follow-up are unlikely to benefit or may be excluded.
Why it matters
Potential benefit: If effective, this approach could lower COPD exacerbations, improve symptoms and quality of life, and provide a structured rehabilitation model for patients with heart or cerebrovascular comorbidity.
How similar studies have performed: Pulmonary rehabilitation is an established therapy that improves symptoms and quality of life in COPD generally, but its targeted use and the proposed integrated 'trinity' management model for patients with cardiovascular or cerebrovascular comorbidity are less well studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Committed to adhering to the study protocol and cooperating with the implementation of the entire research process. 2. Aged 18 years or older, regardless of gender. 3. Signed informed consent form. Exclusion Criteria: 1. Individuals with severe mental illness. 2. Individuals assessed by medical personnel as having a disease that requires immediate hospitalization or a severe, uncontrollable condition that is life-threatening in the short term. 3. Women who are pregnant, breastfeeding, or using inappropriate contraception methods. 4. Individuals who refuse to cooperate with follow-up questionnaires or specimen collection. 5. Patients currently participating in other interventional clinical drug trials.
Where this trial is running
Wuhan, Hubei
- Union hospital, Tongji Medical college, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Guanzhou Ma
- Email: maguanzhouxiehe@126.com
- Phone: 86+13554024801
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.